EP0637335A1 - Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques - Google Patents

Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques

Info

Publication number
EP0637335A1
EP0637335A1 EP93911775A EP93911775A EP0637335A1 EP 0637335 A1 EP0637335 A1 EP 0637335A1 EP 93911775 A EP93911775 A EP 93911775A EP 93911775 A EP93911775 A EP 93911775A EP 0637335 A1 EP0637335 A1 EP 0637335A1
Authority
EP
European Patent Office
Prior art keywords
epitope
recombinant
adenylate cyclase
gene
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93911775A
Other languages
German (de)
English (en)
Other versions
EP0637335B1 (fr
Inventor
Daniel Ladant
Claude Leclerc
Peter Sebo
Agnès ULLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to EP06007083A priority Critical patent/EP1715047A3/fr
Publication of EP0637335A1 publication Critical patent/EP0637335A1/fr
Application granted granted Critical
Publication of EP0637335B1 publication Critical patent/EP0637335B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Definitions

  • This invention relates to a recombinant DNA molecule comprising the adenylate cyclase toxin gene (cyaA) or a fragment thereof containing an insertion of a heterologous DNA sequence at a permissive site, wherein the fragment encodes a polypeptide exhibiting the same immunological properties as the CyaA gene product.
  • the heterologous DNA sequence encodes an immunological epitope.
  • CyaA can be obtained from any microorganism or otherwise.
  • This invention also relates to a recombinant adenylate cyclase comprising a heterologous epitope at a permissive site.
  • the heterologous epitope is inserted in the N-terminal catalytic domain of the recombinant adenylate eye]ase and can be presented to the immune system in association with class I major histocompatability complex (MHC) .
  • MHC major histocompatability complex
  • the heterologous epitope is inserted in the C-terminal catalytic domain and can be presented to the immune system in association with class II MHC.
  • This invention further relates to methods of inducing specific immune responses in animals immunized with immunological compositions comprising recombinant adenylate cyclases.
  • B cell, CD4 + , and cytotoxic T-cell responses are specifically induced.
  • Modification of specific a ino acids .of enzymes of known structure toalter specificity has been achieved by site-directed mutagenesis.
  • Insertional mutagenesis has been efficiently used to study the topology of membrane proteins (Charbit et al., 1986, 1991) and, in the case of soluble proteins, to determine regions of natural flexibility (Barany, 1985a, 1985b; Freimuth and Ginseberg, 1986; Starzyk et al. , 1989; Freimuth et al. , 1990; Kumar and Black, 1991).
  • insertion of a specific exogenous peptide within an enzyme could alter its catalytic or regulatory properties, thus providing a rational basis for protein engineering.
  • protein engineering can be used to alter or specifically direct the immune response to a defined epitope by altering the environment of the epitope.
  • the immune response can ⁇ e divided into two distinct systems, cellular immunity and humoral immunity.
  • Humoral immunity is mediated by soluble molecules, principally antibodies.
  • cellular immunity is mediated by intact cells, mostly T lymphocytes.
  • the exact immune response generated by a foreign antigen is dependent on the nature of the antigen and the environment in which the antigen or an epitope of the antigen is presented to the immune system.
  • the initiating event in a humoral immune response is the binding of a B epitope to a membrane associated immunoglobulin (Ig) on a specific subset of B cells. This binding stimulates the entry of the B cells into the cell cycle, eventually resulting in the production of antibodies specifically recognizing the B epitope.
  • Ig membrane associated immunoglobulin
  • the antibody response elicited by a B epitope can be T cell-dependent or T cell-independent.
  • T cell-dependent responses are characterized by a very low primary response followed by an IgG memory response.
  • the T cell-independent response is characterized by a rapid, intense and prolonged IgM antibody response.
  • T epitopes The cell mediated immune response is activated by T epitopes.
  • T epitopes generally fall into two categories. Many epitopes can activate both T cells and B cells and are thus both T epitopes and B epitopes. Other T epitopes are denatured forms of native antigenic determinants and cannot activate a B cell mediated humoral immune response.
  • MHC major histocompatability complex
  • Class I MHC is a transmembrane protein comprised of two polypeptide chains. The molecule contains an extracellular peptide binding region that is polymorphic at the peptide binding site, an immunoglobulin region, a transmembrane region, and a cytoplasmic domain that contains phosphorylation sites for a cAMP dependent protein kinase.
  • Class I MHC is found on virtually all nucleated cells. Class I MHC generally associate with endogenously synthesized T epitopes for presentation to the cell mediated immune system. As this association of class I MHC to specific antigen occurs in the endoplasmic reticulum, antigens that are internalized by an antigen presenting cell via the endocytotic pathway will generally not become associated with class I MHC. The association of a specific T epitope with class I MHC and incorporation of the antigen-MHC class I complex on the surface of a cell stimulates specific cytotoxic T lymphocytes (CTL) .
  • CTL cytotoxic T lymphocytes
  • the stimulated cytotoxic T lymphocytes can then kill the cell expressing the antigen-MHC complex by granule exocytosis of a membrane pore forming protein that causes cell lysis and secretion of a cell toxin that activates DNA degrading enzymes.
  • the activation of the CTL cells also requires the activation of T helper cells in certain cases.
  • class II MHC The other major class of MHC proteins is class II MHC.
  • Class II MHC are also transmembrane proteins. Like class I MHC, class II MHC comprises two polypeptide chains and includes a polymorphic peptide binding region, an immunoglobulin-like region, a transmembrane region and a cytoplasmic domain. However ⁇ unlike class I MHC, class II molecules are only expressed on "antigen presenting cells" such as B-lymphocytes, macrophages, dendritic cells, endo- thelial cells, and a few others. T-epitopes become associated with class II MHC when an antigen comprising the T epitope binds to the surface of an antigen presenting cell.
  • the antigen enters the cell via phagocytosis or by receptor mediated endocytosis in clathrin coated vesicles.
  • soluble antigens may be internalized by fluid phase pinocytosis. Once the antigen is internalized it is processed by cellular proteases in acidic vesicles resulting in peptides 10-20 amino acids long. These epitopes bind MHC class II molecules in intracellular vesicles and the complex is transported to the cell surface. The presence of the MHC class II-antigen complex on the surface of antigen presenting cells results in the stimulation of subpopulations of T helper cells. These cells aid CTL function as well as B cell responses. In addition, T helper cells can mediate inflammatory responses.
  • T cell epitope that can be targeted to enter an antigen presenting cell in a receptor mediated endocytosis dependent way will become associated with class II MHC and activate T helper cells but not CTL cells.
  • a foreign T cell epitope can be directed to the cytoplasm of a target cell in a receptor mediated endocytosis independent fashion, the epitope will become associated with class I MHC and permit the activation of CTL cells. Therefore, there exists a need in the art to specifically target epitopes in order to selectively activate a cell mediated or humoral immune response.
  • This invention relates to a recombinant plasmid useful for expressing adenylate cyclase, wherein the plasmid comprises the cyaA and the cyaC genes of Bordetella sp. adenylate cyclase, or homologs thereof, operably linked to an expression control sequence, wherein the recombinant plasmid directs the expression of Bordetella sp. adenylate cyclase in a transformed host cell selected from the group consisting of bacteria, eukaryotic cells and yeast.
  • the cyaA gene and the cyaC gene are the cyaA gene and the cyaC gene of Bordetella pe.rtussis.
  • the host cell is E. coli
  • the expression control sequence comprises the lac promoter
  • the cyaA gene comprises DNA encoding a heterologous epitope.
  • the recombinant plasmid is pCACT3.
  • This invention also relates to a recombinant DNA molecule comprising the cyaA adenylate cyclase gene of Bordetella sp. or homologs thereof, wherein the cyaA gene contains at least one insertion of a heterologous DNA sequence at at least one permissive site.
  • the heterologous DNA sequence encodes less than 25 amino acids, between 10-20 aminoacids and 16 amino acids.
  • the heterologous DNA sequence is an epitope of poliovirus, HIV virus, influenza virus, or lymphocytic choriomeningitis virus and is inserted in the N-terminal catalytic domain or the C-terminal domain.
  • This invention further relates to a recombinant Bordetella pertussis adenylate cyclase comprising a heterologous epitope at a permissive site.
  • the adenylate cyclase is in detoxified form.
  • the heterologous epitope is inserted into the N-terminal catalytic domain and the heterologous epitope is presented to CD8 + T lymphocytes in association with molecules of class I major histocompatability complex.
  • the heterologous epitope is inserted into the C-terminal domain and is presented to CD4 + T lymphocytes in association with molecules of class II major histocompatability complex.
  • the permissive site of the Bordetella pertussis adenylate cyclase is selected from the group consisting of residues 137-138, residues 224-225, residues 228-229, residues 235-236 and residues 317-318.
  • the heterologous epitope of the recombinant Bordetella pertussis adenylate cyclase is epitope 118-132 of the nucleoprotein of the lymphocytic choriomeningitis virus, an epitope of HIV virus, in particular the epitope included in the V3 loop, an epitope of influenza virus, or an epitope of poliovirus, in particular epitope 103-116 of poliovirus.
  • this invention relates to a method of inducing a B cell immune response comprising immunizing animals with live bacteria expressing a recombinant adenylate cyclase or an immunological composition comprising a recombinant adenylate cyclase or a fragment of AC, wherein the recombinant adenylate cyclase comprises a heterologous B epitope.
  • the bacteria used in the method of inducing a B cell immune -response are E. coli.
  • the animals immunized with the immunological composition or bacteria are humans.
  • the heterologous B epitope is a poliovirus B epitope, an HIV B epitope, a lymphocytic choriomeningitis virus B epitope, or an influenza virus B epitope.
  • This invention also relates to a method of inducing a CD4 + T cell immune response, wherein the method comprises immunizing animals with an immunological composition comprising a recombinant adenylate cyclase, wherein said recombinant adenylate cyclase comprises a heterologous T epitope at a permissive site in the C-terminal domain of said recombinant adenylate cyclase.
  • the immunological composition further comprises a suitable adjuvant.
  • the heterologous T epitope is a T epitope of poliovirus, HIV, influenza virus, or lymphocytic choriomeningitis virus.
  • This invention further relates to a method of inducing CD8 + T cell immune response, wherein the method comprises immunizing animals with an immunological composition comprising a recombinant adenylate cyclase, wherein the recombinant adenylate cyclase comprises at least one heterologous CTL epitope at at least one permissive -site in the N- terminal catalytic domain of the recombinant adenylate cyclase.
  • the immunological composition further comprises a suitable adjuvant, such as aluminum hydroxide.
  • a suitable adjuvant such as aluminum hydroxide.
  • the heterologous T epitope is a T epitope of poliovirus, HIV, choriomeningitis virus, particularly epitope 118-132 of the nucleoprotein of the choriomeningitis virus, or influenza virus.
  • the Figure represents schematically a method of constructing plasmid pCACT3.
  • This invention relates to recombinant DNA molecules comprising the Bordetella pertussis cyaA gene, wherein the cyaA gene contains an insertion of a heterologous DNA sequence at a permissive site.
  • This invention also relates to a recombinant Bordetella pertussis adenylate cyclase comprising a heterologous epitope at a permissive site.
  • This invention further relates to a method of inducing a CD4 + T-cell immune response comprising immunizing animals with an immunological composition, wherein the immunological composition comprises a recombinant Bordetella pertussis adenylate cyclase with a heterologous T epitope at a permissive site within the C terminal domain.
  • This invention also relates to a method of inducing a CD8 + T cell immune response comprising immunizing animals with an immunological composition wherein the immunological composition comprises a recombinant Bordetella pertussis adenylate cyclase with a heterologous T epitope at a permissive site within the N terminal catalytic domain.
  • expression control sequence refers to a sequence of nucleic acid that regulates the transcription and/or translation of a structural gene. This regulation can be direct or indirect.
  • expression control sequences include promoters, operators, ribosome binding sites and DNA that encodes ribosome binding sites.
  • heterologous DNA sequence refers to a DNA sequence derived from the DNA of a species other than the DNA of the remainder of the molecule or gene in which the heterologous sequence is located.
  • the heterologous DNA sequence can be synthesized enzymatically or chemically. Alternatively, the heterologous DNA sequence may be directly isolated from a source organism.
  • transmissive site refers to a site within the protein molecule, where exogenous amino acids may be added without appreciably affecting the functional properties o ,the protein.
  • the term "permissive site” refers to a site within the nucleic acid, where exogenous nucleotides can be added while maintaining reading frame without appreciably affecting the functional properties of a protein expressed from the nucleic acid.
  • epitope refers to a sequence of amino acids, or another molecule or fragment thereof, that can induce an immune response.
  • B epitope refers to a sequence of amino acids, or another molecule or fragment thereof, that can induce an immune response involving B lymphocytes.
  • heterologous epitope refers to an epitope that can be inserted in a protein • by recombinant techniques wherein the inserted epitope is not naturally found in this protein.
  • E. coli strain XL-1 containing pCACT3 was deposited with the Collection Nationale de Cultures de Micro-organisms of Institut Pasteur, 28 rue du Dondel Roux, 75724 Paris, Cedex 15, France under accension number 1-1201 on April 8,_1992.
  • the mechanisms by which the immunogenicity of defined peptide epitopes is controlled involves both the intrinsic characteristics of a given epitope and environmental factors. These environmental factors include - hether the epitope is exposed as part of complex and organized structures such as parasites or bacteria. By expressing a given peptide epitope-in different permissive sites of various bacterial proteins it is possible to alter the environmental factors and thus specifically modify the immunogenicity of the peptide epitope.
  • the adenylate cyclase of Bordetella pertussis represents a. suitable vehicle to specify the im unogenic response of a heterologous peptide epitope in embodiments of this invention.
  • the Bordetella pertussis adenylate cyclase constitutes one of the essential toxins of this organism which is the causative agent of whooping cough.
  • the adenylate cyclase is secreted by Bordetella pertussis and possesses the ability to enter target eukaryotic cells where, activated by calmodulin (CaM) , it catalyzes the synthesis of cyclic AMP (cAMP) thereby impairing cellular metabolism.
  • CaM calmodulin
  • cAMP cyclic AMP
  • the adenylate cyclase (AC) is synthesized andsecreted in the form of a polypeptide of 1706 amino acids: the calm ⁇ dulin-dependent catalytic activity is localized in the first 400 amino acids.
  • the C-terminal portion of approximately 1300 residues is responsible for the binding to the target cells and for the translocation of the N-terminal catalytic domain through the cytoplasmic membrane of these cells. In addition, this C-terminal portion possesses a weak hemolytic activity.
  • Bordetella pertussis AC Several features of Bordetella pertussis AC indicate that this toxin can be used as a vehicle for inducing a specific immunogenic response:
  • this ' adenylate cyclase is capable of entering many different cells, especially various types of cells associated with the immune system;
  • the adenylate cyclase may be internalized by the target cells independent of a receptor mediated endocytosis process suggesting that the catalytic domain of the toxin is capable of penetrating directly through the cytoplasmic membrane of the target cells;
  • the Bordetella pertussis adenylate cyclase (Cya) toxin-encoding genetic locus (cya) is composed of five genes (cyaA-E) .
  • the cyaA gene encodes the adenylate cyclase.
  • Expression of the cyaA gene in E. coli leads to the production of a 200 kDa gene product exhibiting catalytic activity, but devoid of invasive and hemolytic activities.
  • the coexpression of the cyaC gene product renders the cyaA holotoxin invasive and hemolytic in a reconstituted expression system in E. coli.
  • Coexpression of the cyaB, D, and E genes in trans to cyaA does not confer invasiveness and hemolytic activity upon the holotoxin, nor does it potentiate the activities brought about by the cyaC gene product.
  • CyaC-mediated activation of CyaA results from a post-translational modification. This modification is not lost during toxin purification from B. pertussis by a procedure including 8M urea extraction or SDS-PAGE separation (Hewlett et al., 1989). This finding indicates that the modification is covalent.
  • Expression vectors were constructed directing the expression of both the cyaA gene and the cyaC gene (Sebo et al., 1991). Additionally, another plasmid expression vector, pCACT3, was constructed which contains both the cyaA and cyaC genes. This expression vector permits a second compatible plasmid carrying ⁇ genes necessary for the secretion of the cytotoxic AC in E. coli, such as hlyB and hlyD as described in Meck an et al., 1985. -
  • Plasmid pCACT3 was constructed in several steps (See Figure 1) :
  • plasmid pAHLl was constructed by inserting between the single Pstl and EcoRI sites of plasmid pACM384, the oligonucleotide 5'CTG CAGG TCG ACT CTA GAG GAT CCC CGG GTA CCT AAG TAAC TAA GAA TTC3 ' ;
  • the AC toxin may be expressed in E. coli and/or secreted by this bacterium ' in large amounts, and it-is readily purified (affinity chromatography on CaM Affl-Gel resin) .
  • the plasmids which were used for this identification were derivatives of pDIA5240 (P. Sebo, P. Glaser, H. Sakamoto and A. Ullman, Gene 1991, 104, 19-24, the contents of which are hereby incorporated by reference) containing the first 459 codons of the cyaA gene and which expressed the N- ter inal portion of the AC (399 amino acids) , devoid of all invasive or cytotoxic activity.
  • a PvuII-Bst fragment of pDIA5240 comprising 373bp codons of CyaA was ligated to the 3 ' terminal portion of the gene (3999 base pairs - 1333 codons) .
  • the resulting protein thereby regains, in the presence of the product of the cyaC gene, its invasive power.
  • Additional peptide sequences of 10 to 20 amino acids were then inserted at the previously identified sites in order to analyze the cytotoxicity _of the recombinant toxins. In specific embodiments of this invention this insertion is at restriction sites of the cyaA gene.
  • the modified toxins which retain their cytotoxicity may be used as a vehicle for presentation of antigenic determinants. See Ladant et al., 1992, the contents of which are hereby incorporated by reference. We have defined in this manner five permissive sites in the N-terminal portion of the AC (insertion between amino acids 137-138, 224-225, 228-236, 228-229, 235-236 and 317-318) . A more exhaustive mapping will enable the person of ordinary skill in the art to locate other permissive sites using the methods described herein.
  • toxins can be constructed that are doubly modified - in the N-terminal catalytic domain and in the C-terminal domain - and capable of possessing both epitopes directed to class I MHC and other epitopes directed to class II MHC.
  • B. pertussis AC toxin is used to present epitopes of vaccinal importance to the immune system.
  • This recombinant toxin may be used as a component of the vaccine, either alone or in the presence of other antigenic preparation(s) . It can be used in toxic form or in detoxified form.
  • the detoxified form can be obtained by directed mutagenesis. For example, by replacing Lys58 or Lys65 (Glaser et perennial., 1989, the contents of which are hereby incorporated by reference) by a Gin residue.
  • the detoxified form may be obtained by inserting the oligonucleotide CTG CAG at the EcoRV site at position 564 of the coding phase of the cyaA gene. See Ladant et al. , 1992.
  • DNA encoding B. pertussis adenylate cyclase derivative of the invention can be obtained, by way of example, as follows.
  • Plasmid pDIA5240 is linearized at a restriction site where DNA encoding a heterologous epitope is to be inserted.
  • the restriction site is Nrul when the permissive site is at residues 137-138 or at residues 235-236.
  • the restriction site is Hindlll when the permissive site is at residues 224-225, at residues 228-229, or at residues 317-318.
  • the resulting pDIA5240 derivative containing heterologous epitope(s) at a permissive site is restricted with PvuII and BstBI.
  • a 1.4 Kb fragment is isolated containing the portion of the adenylate cyclase gene coding for the N-terminal catalytic domain and comprising a heterologous epitope.
  • the restriction fragment is then fused to the remainder of cyaA gene by inserting it between the Hindlll site (connected to a blunt-end by T4 DNA polymerase) and BstBI site of pCACT3.
  • the heterologous epitope can be inserted into pDIA5240 as a part of a linker that is compatible with an appropriate permissive site. In specific embodiments of this invention the linker codes for about 16 amino acids.
  • Any epitope recognized by the cells of the immune system, B or T lymphocytes, may be introduced into the permissive sites of the AC.
  • Each molecule of toxin may comprise one or more copies of the same epitope, or a combination of different epitopes, B or T, located in various sites of the toxin.
  • any epitope recognized by B lymphocytes and capable of inducing antibodies possessing biological activity may be introduced into the toxin.
  • the C3 epitope of the polio virus or the V3 epitope of the HIV virus, which are capable of inducing antibodies neutralizing these viruses will be introduced into the toxin.
  • the V3 epitope of the HIV virus to be inserted is RIQRGPGRAFVTIGK (residues 315-329) .
  • V3 epitopes corresponding to the various isolates of the virus may be introduced into various sites of the toxin.
  • recombinant toxins possessing other epitopes of the HIV virus can be prepared.
  • Each molecule of toxin may hence present different B epitopes, in the presence or • absence of other epitopes (and in particular of T epitopes) .
  • the vaccinal preparations may comprise molecules of recombinant toxin possessing different epitopes.
  • these epitopes may be expressed - within other vector proteins.
  • the two E. coli envelope proteins LamB and MalE can be used.
  • LamB E. coli envelope proteins
  • the epitope is expressed on the surface of transformed bacteria as part of the outer membrane protein LamB, a T cell independent antibody response characterized by a rapid induction of IgM and IgG antibodies is induced.
  • the epitope is expressed as part of the periplasmic MalE protein, a T cell dependent antibody response, belonging to the IgG class, is induced.
  • the molecules of recombinant toxin may also be used to present epitopes recognized by CD4 + T lymphocytes. These epitopes will be inserted either alone or in combination with other T or B epitopes. There may thus be inserted the T epitopes 103-116 of the poliovirus, alone or in continuity with the B epitope 93-103, T epitopes of the HIV virus, and in particular the T epitope included in the V3 loop, or the T epitope of the lymphocytic choriomeningitis virus included in the region 118-132 of the nucleoprotein.
  • the sequence of region 118-132 of the nucleoprotein of lymphocytic choriomeningitis virus is RPQASGVYMGNLTAQ.
  • the sequence of the B epitope 93-103 of poliovirus (C3 epitope) is: DNPASTTNKDK
  • the sequence of the T epitope is:
  • the T epitopes will preferably be inserted into the C-terminal region of the toxin capable of entering the presenter cell by an endocytosis pathway.
  • Toxin molecules possessing AC activity or mutated to lose this activity may be used, depending on the type of CD4 * response desired.
  • the recombinant molecule can consist of a fragment or the complete adenylate cyclase protein expressing foreign epitope(s) .
  • mice are immunized with the molecules of recombinant toxin in the presence of suitable adjuvant, such as Freunds' complete adjuvant, Freunds' incomplete adjuvant, or aluminum hydroxide.
  • suitable adjuvant such as Freunds' complete adjuvant, Freunds' incomplete adjuvant, or aluminum hydroxide.
  • the CD4 + T responses are determined by proliferation of lymphocytes (spleen or draining lymph nodes) , cultured with the peptide corresponding to the inserted T epitope as described previously. See Fayolle, et al. , 1991.
  • lymphocytes spleen or draining lymph nodes
  • the recognition by lymphocytes of mice immunized with peptides of molecules of recombinant toxin in vitro is determined by incorporation of thy idine. See Leclerc, et al. 1991.
  • AC toxin possesses the ability to enter the cytoplasm of target cells. This makes it possible to deliver T epitopes recognized by CD8* T lymphocytes to the cytoplasm of these cells, and to permit association of these epitopes with molecules of the class I MHC.
  • Sources of AC are Bordetella sp. , • homologues thereof, or other organisms expressing AC.
  • the adenylate cyclase is a calmodulin dependent AC.
  • the AC is Bordetella pertussis AC.
  • Cytotoxic T responses can be obtained by immunization with the recombinant toxin, alone or in the presence of an adjuvant such as aluminum hydroxide.
  • the routes can be the oral route, the subcutaneous or the intramuscular route.
  • the recombinant toxin expresses one or more epitopes recognized by cytotoxic T cells.
  • Other epitopes in particular epitopes recognized by CD4 + helper T lymphocytes, can be inserted into the same molecule of toxin.
  • the identification of an epitope as a CTL epitope or a T helper epitope is determined experimentally.
  • the epitope 118-132 of the nucleoprotein of the lymphocytic choriomeningitis virus (Aichele, et al. 1990) , which is both a CTL and a T helper epitope.
  • the amino acid sequence of this epitope is: RPQASGVYMGNLTAQ.
  • Epitopes of other pathogens and in particular of HIV can be inserted (CTL epitopes of the env, gag, nef proteins, etc.). Examples of suitable epitopes are described by Nixon et al., 1992, which is expressly incorporated herein by reference.
  • epitopes representing the sequences of various isolates of the HIV virus can be introduced into the same molecule of toxin.
  • Lymphocytes obtained from animals immunized with the recombinant toxin are stimulated for 5 days with syngeneic cells coated with the peptide corresponding to the inserted epitope, or in the presence of the recombinant toxin.
  • the detection of cytotoxic T effectors is carried out as described previously
  • the target cells labeled with chromium-5l ([51Cr]) and possessing the class I molecules compatible with the effector cells, are incubated beforehand with the peptide corresponding to the CTL epitope inserted into the recombinant toxin.
  • the cytotoxic T response is estimated by release of
  • the recombinant AC toxin can be used to target cell antigens and receptors.
  • fusion proteins containing the first 1490 amino acids of the AC this truncated form of the toxin is incapable of binding to the target cells and is hence nottoxic
  • a growth factor such as TGF- ⁇ (in which the target is the EGF receptor)
  • IL-2, IL-4 or IL-6 or any other lymphokine variable regions of antibodies having a strong affinity with receptors or antigens to be targeted, for example tumor antigens
  • TGF- ⁇ in which the target is the EGF receptor
  • B. pertussis AC toxin compared to other immunotoxins lies in the fact that the poisoning of the target cells by the AC is independent of a receptor mediated endocytosis process.
  • any surface marker specific to a given cell could serve as a receptor for targeting the recombinant AC toxin comprising a truncated AC toxin fused with a specific ligand.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Plasmide de recombinaison comprenant les gènes cyaC et cyaA de Bordetella qui dirige l'expression de l'adénylate cyclase de Bordetella dans une cellule hôte transformée. Une molécule d'ADN de recombinaison peut comprendre le gène cyaA de Bordetella contenant au moins une insertion d'une séquence d'ADN de recombinaison au niveau d'au moins un site permissif. En outre une adénylate cyclase de Bordetella de recombinaison comprend un déterminant antigénique situé au niveau d'un site permissif. Sont également décrits des procédés permettant d'induire une réponse immunitaire spécifique des cellules B, des cellules T auxiliaires et des cellules des lymphocytes T cytotoxiques.
EP93911775A 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques Expired - Lifetime EP0637335B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06007083A EP1715047A3 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des réponses immunitaires spécifiques

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87179592A 1992-04-21 1992-04-21
US871795 1992-04-21
US1164493A 1993-01-29 1993-01-29
US11644 1993-01-29
PCT/EP1993/000977 WO1993021324A1 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06007083A Division EP1715047A3 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des réponses immunitaires spécifiques

Publications (2)

Publication Number Publication Date
EP0637335A1 true EP0637335A1 (fr) 1995-02-08
EP0637335B1 EP0637335B1 (fr) 2007-07-25

Family

ID=26682623

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06007083A Withdrawn EP1715047A3 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des réponses immunitaires spécifiques
EP93911775A Expired - Lifetime EP0637335B1 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des reponses immunitaires specifiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06007083A Withdrawn EP1715047A3 (fr) 1992-04-21 1993-04-21 Mutants de recombinaison permettant d'induire des réponses immunitaires spécifiques

Country Status (9)

Country Link
US (2) US5503829A (fr)
EP (2) EP1715047A3 (fr)
AT (1) ATE368113T1 (fr)
CA (1) CA2133999A1 (fr)
DE (1) DE69334155T2 (fr)
DK (1) DK0637335T3 (fr)
ES (1) ES2290950T3 (fr)
PT (1) PT637335E (fr)
WO (1) WO1993021324A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323426A1 (fr) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Compositions d'immunogènes et de vaccins contre l'infection par bordetella bronchiseptica
WO2018091613A1 (fr) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Compositions immunogènes et vaccinales pour utilisation contre une infection par bordetella bronchiseptica

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
CA2377525A1 (fr) * 1999-07-19 2001-03-29 Epimmune, Inc. Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
ATE445643T1 (de) * 1999-11-18 2009-10-15 Pharmexa Inc Heteroklitische analoga von klasse-i epitopen
CA2393662A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2394741A1 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
FR2805544B1 (fr) * 2000-02-28 2004-07-16 Pasteur Institut Adenylcyclase recombinante et procede de tri de molecules a activite proteolytique utilisant cette adenylcyclase
CN1454082A (zh) * 2000-09-08 2003-11-05 艾普免疫公司 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答
ES2331348T3 (es) * 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
AU2007203473B2 (en) * 2000-09-15 2011-04-14 Centre National De La Recherche Scientifique Vectors for Molecule Delivery to CD11b Expressing Cells
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
DE10211063A1 (de) * 2002-03-13 2003-10-09 Axaron Bioscience Ag Neue Verfahren zur Detektion und Analyse von Protein-Interaktionen in vivo
EP1609107A4 (fr) * 2003-03-28 2006-08-30 Idm Pharma Inc Procedes d'identification de variants optimaux d'epitopes peptidiques
WO2004098526A2 (fr) 2003-05-05 2004-11-18 Johns Hopkins University Vaccin a adn anti-cancer faisant appel a des plasmides codant une sequence-signal, un antigene oncoproteine mutant, et une proteine de choc thermique
EP1489092A1 (fr) 2003-06-18 2004-12-22 Institut Pasteur Adényl cyclase de Bordetella modifié avec ou sans le CD11b/CD18 domaine d'interaction et son utilisations
WO2005035557A2 (fr) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylcyclase intervenant dans le traitement et/ou la prophylaxie d'une maladie a mediation immunitaire
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
EP1716415A1 (fr) * 2003-11-21 2006-11-02 Institut Pasteur Adenylate cyclase recombinante de bordetella sp. a usage de diagnostic et suivi immunologique, methode de diagnostic et suivi immunologique utilisant ladite adenylate cyclase, et trousse pour le diagnostic et suivi immunologique comprenant ladit adenylate cyclase recombinante
WO2005053738A1 (fr) * 2003-11-21 2005-06-16 Institut Pasteur Toxine d'adenylate-cyclase recombinante de bordetella induisant des reponses des lymphocytes t contre des antigenes tumoraux
DK1576967T3 (da) * 2004-03-18 2008-01-21 Pasteur Institut Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
US20060286613A1 (en) * 2004-11-19 2006-12-21 Claude Leclerc Recombinant adenylate cyclase of Bordetella sp. for diagnostic and immunomonitoring uses, method of diagnosing or immunomonitoring using said recombinant adenylate cyclase, and kit for diagnosing or immunomonitoring comprising said recombinant adenylate cyclase
WO2007079448A2 (fr) * 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Vaccin glucidique à trois composants
WO2008137115A1 (fr) * 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Cellules souches multipotentes et leurs utilisations
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2736799A1 (fr) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Epitope conserve d'hemagglutinine, anticorps contre l'epitope et procedes d'utilisation
EP2233569B1 (fr) 2009-03-23 2014-06-25 Institut Pasteur Polypeptides CyaA mutants et dérivés de polypeptides adaptés à la fourniture de molécules immunogènes dans une cellule
JP5770711B2 (ja) 2009-03-23 2015-08-26 アンスティテュ パストゥール 細胞中への免疫原性分子のデリバリーに適したＣｙａＡポリペプチド突然変異体及びポリペプチド誘導体
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
EP2478915A1 (fr) 2011-01-24 2012-07-25 Genticel Polypeptide(s) transporté(s) par CYAA et utilisation pour induire des réponses immunes tant thérapeutiques que prophylactiques
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182211A (en) * 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) * 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
FR2638169B1 (fr) * 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
EP0406857B1 (fr) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Protéines et leur production
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9321324A1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323426A1 (fr) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Compositions d'immunogènes et de vaccins contre l'infection par bordetella bronchiseptica
WO2018091613A1 (fr) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Compositions immunogènes et vaccinales pour utilisation contre une infection par bordetella bronchiseptica

Also Published As

Publication number Publication date
EP1715047A3 (fr) 2008-08-27
DK0637335T3 (da) 2007-11-26
DE69334155T2 (de) 2008-02-14
ES2290950T3 (es) 2008-02-16
WO1993021324A1 (fr) 1993-10-28
EP0637335B1 (fr) 2007-07-25
PT637335E (pt) 2007-10-31
ATE368113T1 (de) 2007-08-15
DE69334155D1 (de) 2007-09-06
CA2133999A1 (fr) 1993-10-28
US5679784A (en) 1997-10-21
EP1715047A2 (fr) 2006-10-25
US5503829A (en) 1996-04-02

Similar Documents

Publication Publication Date Title
US5503829A (en) Recombinant mutants for inducing specific immune responses
US5935580A (en) Recombinant mutants for inducing specific immune responses
EP0689551B1 (fr) Chimeres immunogenes comportant des sequences d'acide nucleique codant des peptides de sequence-signal de reticulum endoplasmique et au moins un autre peptide, et leur utilisation dans les vaccins et le traitement de maladies
EP0378881B1 (fr) Peptides synthétiques et leur utilisation comme support universel pour la préparation de conjugués immunogènes convenant au développement de vaccins synthétiques
Carbone et al. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.
JP3428646B2 (ja) ジフテリア毒素ワクチン
US5500366A (en) Polynucleotide encoding T-cell epitopes of the protein TraT
US7097965B2 (en) Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein
EP0712442B1 (fr) Compositions vaccinales
US6881828B2 (en) Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
Romero et al. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule.
CA2343051A1 (fr) Compositions de proteines c beta streptococciques
KR100338894B1 (ko) 백신조성물
AU615940B2 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
KR960005181B1 (ko) 재조합 htlv-ⅲ 단백질 및 이의 용도
JPH05345800A (ja) 細菌毒素−抗原複合体からの細胞免疫ワクチン
EP0212532A1 (fr) Méthode pour produire des protéines de fusion
EP0213472A1 (fr) Méthode pour produire des protéines de fusion
Fayolle et al. Bordetella pertussis adenylate cyclase delivers chemically coupled CD8+ T-cell epitopes to dendritic cells and elicits CTL in vivo
EP0250261A1 (fr) Vaccins contenant des épitopes aussi bien de CSP que d'un antigène du stade sanguin d'un parasite plasmodium
JPS63503197A (ja) マラリアに対する保護免疫を与えるポリペプチド類
EP0550558A1 (fr) Vaccin acellulaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000404

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/10 20060101ALI20061129BHEP

Ipc: C12N 15/62 20060101ALI20061129BHEP

Ipc: C12N 9/88 20060101ALI20061129BHEP

Ipc: C12N 15/31 20060101AFI20061129BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69334155

Country of ref document: DE

Date of ref document: 20070906

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20071019

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070403090

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2290950

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080428

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20120323

Year of fee payment: 20

Ref country code: LU

Payment date: 20120326

Year of fee payment: 20

Ref country code: MC

Payment date: 20120319

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20120319

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20120327

Year of fee payment: 20

Ref country code: DK

Payment date: 20120323

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20120326

Year of fee payment: 20

Ref country code: DE

Payment date: 20120416

Year of fee payment: 20

Ref country code: CH

Payment date: 20120419

Year of fee payment: 20

Ref country code: BE

Payment date: 20120430

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120511

Year of fee payment: 20

Ref country code: SE

Payment date: 20120423

Year of fee payment: 20

Ref country code: GB

Payment date: 20120423

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120423

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120425

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120322

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69334155

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69334155

Country of ref document: DE

BE20 Be: patent expired

Owner name: INSTITUT PASTEUR

Effective date: 20130421

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20130421

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130421

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130420

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 368113

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130421

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20070403090

Country of ref document: GR

Effective date: 20130422

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130423

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130502

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130421